Large Doses of Cisplatin and Endostatin Perfusion in ShenShi Combined with Thalidomide in Treatment of Advanced Liver Cancer

余安平,李凌,冯龙,蒋为民,吴建兵,郭武华,魏建平

DOI: https://doi.org/10.13267/j.cnki.syzlzz.2012.03.026

2012-01-01

Abstract:Objective To reseach the new therapy wich may raise the survival for the patients with advanced liver cancer who are not suitable for surgical resection.Methods All patients were randomly assigned to two groups: treatment group and control group and each group consisted of 30 cases.In treatment group,proximally before TACE(transcatheter arterial chemoembolization),each member was given orally thalidomide 50 mg,tid,in continuous 14 days.On the same afternoon each member was treated by means of hydration.Next day the large doses of cisplatin(90～180 mg),5-FU(1.0 g) were infused into the tumor's blood-supply artery within 3 PM to 5 PM(ShenShi) by means of Seldinger's.Simultaneously doxorubicin(40～50 mg) emulsified in UFL(10～20 mL) completely and endostatin(30 mg) were infused by means of sandwich.In control group: except using the large dose of cisplatinr and endostatin hepatic artery perfusion in ShenShi and thalidomaide,the treatments were the same as treatment group.After 1-2 months,the same treatment might be given repeatedly according to the situation.OSR(overall survival) was regarded as the primary endpoint and TTP(the time to disease progression) as the secondary endpoint.Statistical software SPSS 11.5 was used to analyze the data.Results(1) Compared with the control group,the OSR of the treatment group was better significantly.The 1-,2-year survival was 48.78%,30.02% vs 33.33%,16.67%,respectively;the medial survival was 10.84 months vs 8.00 months(P=0.0452).(2) Compared with the control group,the TTP of the treatment group was much longer as well.The 1-,2-year TTP was 38.31%,16.60% vs 16.67%,16.67%,respectively;the medial TTP was 8.97 months vs 5.80 months(P=0.0435).(3) The toxic reaction such as liver and kidney function damage and blood routine examination especially the reduction of white blood cells that reflected the index of function of bone marrow,and gastrointestinal reaction was not significantly different between the two groups.Conclusion The effect of large doses of cisplatin and endostatin perfusion in ShenShi combined with thalidomide for advanced liver cancer is satisfactory and better than conventional TACE treatment,which is worth studying furthermore.